These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29866607)

  • 1. Survivals after liver transplantation for hepatocellular carcinoma: Granular data for a better allocation process?
    Lai Q; Rossi M
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):374-375. PubMed ID: 29866607
    [No Abstract]   [Full Text] [Related]  

  • 2. Expanding transplant criteria for hepatocellular carcinoma: small steps down a long road.
    Sanchez W
    Hepatology; 2009 Mar; 49(3):724-5. PubMed ID: 19241486
    [No Abstract]   [Full Text] [Related]  

  • 3. Is there an ideal cutoff for α-fetoprotein as an exclusion criterion for liver transplantation?
    de Mattos AA; dos Santos Schraiber L; Zanotell ML; Cantisani G
    Liver Transpl; 2014 Oct; 20(10):1284. PubMed ID: 25044482
    [No Abstract]   [Full Text] [Related]  

  • 4. Downstaging of hepatocellular carcinoma before transplantation: an advance in therapy or just another selection criterion.
    Lo C
    Am J Transplant; 2008 Dec; 8(12):2485-6. PubMed ID: 19032218
    [No Abstract]   [Full Text] [Related]  

  • 5. α-Fetoprotein and hepatocellular cancer recurrence: a paradigm of the chaos theory.
    Lai Q; Lerut J;
    Liver Transpl; 2014 Oct; 20(10):1283. PubMed ID: 25060782
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to letter to the editors.
    Yao FY; Hameed B; Mehta N; Roberts JP
    Liver Transpl; 2014 Oct; 20(10):1285. PubMed ID: 25155484
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial on "a revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor liver transplantation in hepatocellular carcinoma".
    Lo CM
    Surgery; 2007 Jul; 142(1):119-20. PubMed ID: 17630008
    [No Abstract]   [Full Text] [Related]  

  • 8. What is the best staging system for hepatocellular carcinoma?
    Kudo M
    J Gastroenterol; 2006 Mar; 41(3):290-1. PubMed ID: 16699867
    [No Abstract]   [Full Text] [Related]  

  • 9. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation.
    Toso C; Meeberg G; Hernandez-Alejandro R; Dufour JF; Marotta P; Majno P; Kneteman NM
    Hepatology; 2015 Jul; 62(1):158-65. PubMed ID: 25777590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should a biopsy precede liver resection or transplantation for presumed hepatocellular carcinoma when the alfa fetoprotein is normal?
    Shawcross DL; Naoumov N; Pachiadakis I; Mamais C; Williams R; Jalan R; Gillams A; Lees W
    Transplantation; 2004 Feb; 77(4):637-8. PubMed ID: 15084957
    [No Abstract]   [Full Text] [Related]  

  • 12. Usefulness of preoperative C-reactive protein and alpha-fetoprotein levels for prognostication of patients with hepatocellular carcinoma after living donor liver transplantation.
    Mori S; Choi Y; Park MS; Kim H; Hong G; Yi NJ; Lee KW; Suh KS
    Hepatogastroenterology; 2014; 61(136):2353-8. PubMed ID: 25699382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma.
    Shindoh J; Sugawara Y; Nagata R; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Tanaka T; Kokudo N
    Transpl Int; 2014 Apr; 27(4):391-8. PubMed ID: 24472068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of patients with hepatocellular carcinoma before liver transplantation: need to combine alpha-fetoprotein with morphology?
    Toso C; Mentha G; Majno P
    Hepatobiliary Pancreat Dis Int; 2010 Oct; 9(5):460-1. PubMed ID: 20943453
    [No Abstract]   [Full Text] [Related]  

  • 15. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
    Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
    Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients.
    Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Yi NJ; Lee KU
    Liver Transpl; 2006 Nov; 12(11):1655-60. PubMed ID: 16964589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic effect of steatosis on hepatocellular carcinoma patients after liver resection.
    Wu TH; Yu MC; Chan KM; Lee CF; Chen TC; Chang HC; Chou HS; Wu TJ; Eldeen FZ; Chen MF; Lee WC
    Eur J Surg Oncol; 2011 Jul; 37(7):618-22. PubMed ID: 21640545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison between alpha-fetoprotein and p53 antibodies in the diagnosis of hepatocellular carcinoma.
    Edis C; Kähler C; Klotz W; Herold M; Feichtinger H; Königsreiner A; Margreiter R; Jaschke W; Vogel W
    Transplant Proc; 1998 May; 30(3):780-1. PubMed ID: 9595095
    [No Abstract]   [Full Text] [Related]  

  • 19. AFP in OLT for HCC?: Another shadow on the cave wall: Comment on "Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer".
    Cameron AM
    Arch Surg; 2011 Jan; 146(1):33-4. PubMed ID: 21305708
    [No Abstract]   [Full Text] [Related]  

  • 20. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy.
    Firl DJ; Kimura S; McVey J; Hashimoto K; Yeh H; Miller CM; Markmann JF; Sasaki K; Aucejo FN
    Hepatology; 2018 Oct; 68(4):1448-1458. PubMed ID: 29604231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.